The immune system and gastrointestinal stromal tumor: a wealth of opportunities

Yaohong Tan, Monica Garcia-Buitrago, Jonathan Trent, Andrew Rosenberg

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: This article reviews the current literature on tumor-infiltrating immune cells in gastrointestinal stromal tumor (GIST), and the current status and prospects of effective immunotherapeutic strategies.

RECENT FINDINGS: Tumor-infiltrating immune cells populate the microenvironment of GISTs; the most numerous are tumor-associated macrophages (TAMs) and CD3 T cells. TAMs have not been shown to have a relationship with the biological behavior of GISTs; however, the number of CD3 T cells correlates with better outcomes. The prognostic significance of tumor-infiltrating neutrophils, natural killer cells, CD4 T cells, CD8 T cells, and Treg cells remains unknown.Imatinib mesylate achieves a clinical response in 80% of patients with GIST. Its antitumor mechanism is partially immune mediated. The combination of imatinib and interferon-α has been shown to be effective against GIST - it eradicates tumor cells including those that are drug resistant. Preclinical trials including cytotoxic T lymphocyte-associated antigen 4 blockade, anti-KIT antibody, and the generation of designer T cells have shown promising therapeutic effect in animal models of GIST.

SUMMARY: GIST contains many tumor-infiltrating immune cells and should be susceptible to immunotherapy; early clinical and preclinical trials have shown promising results that should lead to new investigations and effective forms of direct and synergistic therapies.

Original languageEnglish (US)
Pages (from-to)338-342
Number of pages5
JournalCurrent Opinion in Oncology
Volume27
Issue number4
DOIs
StatePublished - Jul 1 2015

Fingerprint

Gastrointestinal Stromal Tumors
Immune System
T-Lymphocytes
Neoplasms
Macrophages
CTLA-4 Antigen
Cellular Microenvironment
Therapeutic Uses
Regulatory T-Lymphocytes
Natural Killer Cells
Immunotherapy
Interferons
Anti-Idiotypic Antibodies
Neutrophils
Animal Models
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The immune system and gastrointestinal stromal tumor : a wealth of opportunities. / Tan, Yaohong; Garcia-Buitrago, Monica; Trent, Jonathan; Rosenberg, Andrew.

In: Current Opinion in Oncology, Vol. 27, No. 4, 01.07.2015, p. 338-342.

Research output: Contribution to journalArticle

@article{2a0ccdc1684d4c31b83068ba54570aba,
title = "The immune system and gastrointestinal stromal tumor: a wealth of opportunities",
abstract = "PURPOSE OF REVIEW: This article reviews the current literature on tumor-infiltrating immune cells in gastrointestinal stromal tumor (GIST), and the current status and prospects of effective immunotherapeutic strategies.RECENT FINDINGS: Tumor-infiltrating immune cells populate the microenvironment of GISTs; the most numerous are tumor-associated macrophages (TAMs) and CD3 T cells. TAMs have not been shown to have a relationship with the biological behavior of GISTs; however, the number of CD3 T cells correlates with better outcomes. The prognostic significance of tumor-infiltrating neutrophils, natural killer cells, CD4 T cells, CD8 T cells, and Treg cells remains unknown.Imatinib mesylate achieves a clinical response in 80{\%} of patients with GIST. Its antitumor mechanism is partially immune mediated. The combination of imatinib and interferon-α has been shown to be effective against GIST - it eradicates tumor cells including those that are drug resistant. Preclinical trials including cytotoxic T lymphocyte-associated antigen 4 blockade, anti-KIT antibody, and the generation of designer T cells have shown promising therapeutic effect in animal models of GIST.SUMMARY: GIST contains many tumor-infiltrating immune cells and should be susceptible to immunotherapy; early clinical and preclinical trials have shown promising results that should lead to new investigations and effective forms of direct and synergistic therapies.",
author = "Yaohong Tan and Monica Garcia-Buitrago and Jonathan Trent and Andrew Rosenberg",
year = "2015",
month = "7",
day = "1",
doi = "10.1097/CCO.0000000000000201",
language = "English (US)",
volume = "27",
pages = "338--342",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The immune system and gastrointestinal stromal tumor

T2 - a wealth of opportunities

AU - Tan, Yaohong

AU - Garcia-Buitrago, Monica

AU - Trent, Jonathan

AU - Rosenberg, Andrew

PY - 2015/7/1

Y1 - 2015/7/1

N2 - PURPOSE OF REVIEW: This article reviews the current literature on tumor-infiltrating immune cells in gastrointestinal stromal tumor (GIST), and the current status and prospects of effective immunotherapeutic strategies.RECENT FINDINGS: Tumor-infiltrating immune cells populate the microenvironment of GISTs; the most numerous are tumor-associated macrophages (TAMs) and CD3 T cells. TAMs have not been shown to have a relationship with the biological behavior of GISTs; however, the number of CD3 T cells correlates with better outcomes. The prognostic significance of tumor-infiltrating neutrophils, natural killer cells, CD4 T cells, CD8 T cells, and Treg cells remains unknown.Imatinib mesylate achieves a clinical response in 80% of patients with GIST. Its antitumor mechanism is partially immune mediated. The combination of imatinib and interferon-α has been shown to be effective against GIST - it eradicates tumor cells including those that are drug resistant. Preclinical trials including cytotoxic T lymphocyte-associated antigen 4 blockade, anti-KIT antibody, and the generation of designer T cells have shown promising therapeutic effect in animal models of GIST.SUMMARY: GIST contains many tumor-infiltrating immune cells and should be susceptible to immunotherapy; early clinical and preclinical trials have shown promising results that should lead to new investigations and effective forms of direct and synergistic therapies.

AB - PURPOSE OF REVIEW: This article reviews the current literature on tumor-infiltrating immune cells in gastrointestinal stromal tumor (GIST), and the current status and prospects of effective immunotherapeutic strategies.RECENT FINDINGS: Tumor-infiltrating immune cells populate the microenvironment of GISTs; the most numerous are tumor-associated macrophages (TAMs) and CD3 T cells. TAMs have not been shown to have a relationship with the biological behavior of GISTs; however, the number of CD3 T cells correlates with better outcomes. The prognostic significance of tumor-infiltrating neutrophils, natural killer cells, CD4 T cells, CD8 T cells, and Treg cells remains unknown.Imatinib mesylate achieves a clinical response in 80% of patients with GIST. Its antitumor mechanism is partially immune mediated. The combination of imatinib and interferon-α has been shown to be effective against GIST - it eradicates tumor cells including those that are drug resistant. Preclinical trials including cytotoxic T lymphocyte-associated antigen 4 blockade, anti-KIT antibody, and the generation of designer T cells have shown promising therapeutic effect in animal models of GIST.SUMMARY: GIST contains many tumor-infiltrating immune cells and should be susceptible to immunotherapy; early clinical and preclinical trials have shown promising results that should lead to new investigations and effective forms of direct and synergistic therapies.

UR - http://www.scopus.com/inward/record.url?scp=84959073287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959073287&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000201

DO - 10.1097/CCO.0000000000000201

M3 - Article

C2 - 26049274

AN - SCOPUS:84959073287

VL - 27

SP - 338

EP - 342

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -